GU CONNECT has summarised the highlights from ASCO for you.


GU cancer update by Prof. Sandy Srinivas, Stanford University Medical Center, Palo Alto CA, USA.

GU CONNECT member and genitourinary oncology expert Prof. Sandy Srinivas gives us an insight into new data presented at this years ASCO 2020 virtual conference. In this video discussion with accompanying slides, Prof. Sandy Srinivas highlights drug trials of interest and gives her expert opinion on the latest results of these trials, focusing on practice changing data. The aim of these slides and video is to provide support for medical urologists and oncologists.

The HERO phase III trial and advanced prostate cancer

Focal trials include the pivotal HERO phase 3 trial which compares relugolix, an oral GnRH receptor antagonist, to leuprolide acetate, a GnRH receptor agonist, in treatment of advanced prostate cancer. Discussed is the ability of relugolix to suppress testosterone compared to leuprolide, and clinical considerations for patient suitability.

The TheraP phase II trial and metastatic prostate cancer

Prof. Srinivas then addresses the initial results from the TheraP trial, a randomised phase 2 trial comparing 177LU-PSMA-617 to intravenous cabazitaxel in metastatic castration resistant prostate cancer (mCRPC). The radiolabelled small molecule 177LU-PSMA-617 targets therapeutic β-radiation to PSMA-expressing tumours. Patient outcomes, safety, and prostate specific antigen (PSA) results from this trial are examined. From these data, in context of the phase 3 VISION trial, Prof. Srinivas comments on the potential for drug sequencing in patients with mCRPC.

The IMvigor010 phase III trial; a new concept in targeting urothelial carcinoma

Next, data is covered from the IMvigor010 phase 3 study of adjuvant atezolizumab versus observation in high-risk muscle-invasive urothelial carcinoma (MIUC). This study represents an important concept in the treatment of MIUC, for which cystectomy, with or without cisplatin-based neoadjuvant chemotherapy, is the current standard of care. This trial examines the immune checkpoint inhibitor atezolizumab as adjuvant immunotherapy following cystectomy.

The Javelin 100 trial and emerging treatments in urothelial carcinoma

Prof. Srinivas then focuses on the phase 3 Javelin 100 trial, in which the immune checkpoint inhibitor avelumab is compared to best standard of care in patients with locally advanced or metastatic urothelial carcinoma previously treated with first-line platinum chemotherapy. Underscored are results in overall survival and progression-free survival. Shortly after the ASCO 2020 conference the FDA approved avelumab as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma following the results from the Javelin 100 trial.

Updates in androgen deprivation therapy in non-metastatic CRPC

Lastly, Prof Srinivas discusses updates in androgen deprivation therapy (ADT) for the treatment of patients with non-metastatic CRPC. Highlighted are three trials of FDA approved drugs: apalutamide, darolutamide, and enzalutamide. Focus from new data is on improvements in overall survival and hazard ratios. We hope that you find our video overview and slides insightful.

Sandy Srinivas specializes in urologic oncology and takes care of patients with prostate, bladder, kidney, testes, penile and adrenal cancers. She has practised in this field now for more than 20 years. She is the clinical research group leader for Urologic Program at Stanford and is a principal investigator on numerous trials in urologic Oncology and is the medical director for the in-patient hematology Oncology unit. She serves as the Vice-chair on the National Comprehensive Cancer Center (NCCN) panel for prostate cancer and has co-authored numerous publications and book chapters. She has received numerous teaching awards and is a nationally recognized expert in the field of Urologic Oncology.
GU CONNECT Update from ASCO GU 2020

Episode

3

of

episodes
GU CONNECT
GU CONNECT Update from ASCO GU 2020

Episode 3: Kidney Cancer

Experts
Assoc. Prof. Martin Pichler
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
GU CONNECT Update from ASCO GU 2020

Episode

2

of

episodes
GU CONNECT
GU CONNECT Update from ASCO GU 2020

Episode 2: Urothelial Cancer

Experts
Assoc. Prof. Shilpa Gupta
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
GU CONNECT: Update from ASCO GU 2020

Episode

1

of

episodes
GU CONNECT
GU CONNECT: Update from ASCO GU 2020

Episode 1: Prostate Cancer

Experts
Dr Neal D. Shore
  • download Downloadable
    Resouces
  • clock 5 MIN
  • calendar Oct 2021
This educational programme is supported by an Independent Medical Education Grant from Bayer
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.